ERK1/2-PPARγ pathway is involved in Chlamydia pneumonia-induced human umbilical vein endothelial cell apoptosis through increased LOX-1 expression

References

• Chistiakov DA, Revin VV, Sobenin IA, et al. Vascular endothelium: functioning in norm, changes in atherosclerosis and current dietary approaches to improve endothelial function. MRMC. 2015;15:338–350.
   Google Scholar
• Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832–1844.
   PubMed Web of Science ®Google Scholar
• Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955–1960.
   PubMed Web of Science ®Google Scholar
• Chen M, Kakutani M, Minami M, et al. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol. 2000;20:1107–1115.
   PubMed Web of Science ®Google Scholar
• Cominacini L, Pasini AF, Garbin U, et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem. 2000;275:12633–12638.
   PubMed Web of Science ®Google Scholar
• Chen J, Mehta JL, Haider N, et al. Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res. 2004;94:370–376.
   PubMed Web of Science ®Google Scholar
• Campbell LA, Kuo CC. Chlamydia pneumoniae–an infectious risk factor for atherosclerosis? Nat Rev Microbiol. 2004;2:23–32.
   PubMed Web of Science ®Google Scholar
• Khan S, Rahman HN, Okamoto T, et al. Promotion of atherosclerosis by Helicobacter cinaedi infection that involves macrophage-driven proinflammatory responses. Sci Rep. 2015;4:4680.
   Web of Science ®Google Scholar
• Blessing E, Campbell LA, Rosenfeld ME, et al. Chlamydia pneumoniae and hyperlipidemia are co-risk factors for atherosclerosis: infection prior to induction of hyperlipidemia does not accelerate development of atherosclerotic lesions in C57BL/6J mice. Infect Immun. 2002;70:5332–5334.
   PubMed Web of Science ®Google Scholar
• Blessing E, Campbell LA, Rosenfeld ME, et al. Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice. Atherosclerosis. 2001;158:13–17.
   PubMed Web of Science ®Google Scholar
• Herrera VL, Shen L, Lopez LV, et al. Chlamydia pneumoniae accelerates coronary artery disease progression in transgenic hyperlipidemia-genetic hypertension rat model. Mol Med. 2003;9:135–142.
   PubMed Web of Science ®Google Scholar
• Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost. 2011;106:858–867.
   PubMed Web of Science ®Google Scholar
• Gui T, Shimokado A, Sun Y, et al. Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediators Inflamm. 2012;2012:1–14.
   Google Scholar
• Khallou-Laschet J, Varthaman A, Fornasa G, et al. Macrophage plasticity in experimental atherosclerosis. PLoS One. 2010;5:e8852.
   PubMed Web of Science ®Google Scholar
• Fujii D, Yoshida K, Tanabe K, et al. The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest. Anticancer Res. 2004;24:1409–1416.
   PubMed Web of Science ®Google Scholar
• Chawla A, Repa JJ, Evans RM, et al. Nuclear receptors and lipid physiology: opening the X-files. Science. 2001;294:1866–1870.
   PubMed Web of Science ®Google Scholar
• Shao D, Lazar MA. Modulating nuclear receptor function: may the phos be with you. J Clin Invest. 1999;103:1617–1618.
   PubMed Web of Science ®Google Scholar
• Warford AL, Rekrut KA, Levy RA, Drill AE. Sucrose phosphate glutamate for combined transport of chlamydial and viral specimens. Am J Clin Pathol. 1984;81:762–764.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Koide N, Mori I, et al. Chlamydia pneumoniae infection enhances lectin-like oxidized low-density lipoprotein receptor (LOX-1) expression on human endothelial cells. FEMS Microbiol Lett. 2006;260:17–22.
   PubMed Web of Science ®Google Scholar
• Campbell LA, Lee AW, Rosenfeld ME, et al. Chlamydia pneumoniae induces expression of pro-atherogenic factors through activation of the lectin-like oxidized LDL receptor-1. Pathog Dis. 2013;69:1–6.
   PubMed Web of Science ®Google Scholar
• Yoshimoto R, Fujita Y, Kakino A, et al. The discovery of LOX-1, its ligands and clinical significance. Cardiovasc Drugs Ther. 2011;25:379–391.
   PubMed Web of Science ®Google Scholar
• Ogura S, Kakino A, Sato Y, et al. Lox-1: the multifunctional receptor underlying cardiovascular dysfunction. Circ J. 2009;73:1993–1999.
   PubMed Web of Science ®Google Scholar
• Sessa R, Nicoletti M, Di Pietro M, et al. Chlamydia pneumoniae and atherosclerosis: current state and future prospectives. Int J Immunopathol Pharmacol. 2009;22:9–14.
   PubMed Web of Science ®Google Scholar
• He P, Mei C, Cheng B, et al. Chlamydia pneumoniae induces macrophage-derived foam cell formation by up-regulating acyl-coenzyme A: cholesterol acyltransferase 1. Microbes Infect. 2009;11:157–163.
   PubMed Web of Science ®Google Scholar
• Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37–40.
   PubMed Web of Science ®Google Scholar
• Cheng B, Wu X, Sun S, et al. MAPK-PPARalpha/gamma signal transduction pathways are involved in Chlamydia pneumoniae-induced macrophage-derived foam cell formation. Microb Pathog. 2014; 69–70:1–8.
   PubMed Web of Science ®Google Scholar
• Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298:1911–1912.
   PubMed Web of Science ®Google Scholar
• Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther. 2006;110:371–385.
   PubMed Web of Science ®Google Scholar
• Collins AR, Meehan WP, Kintscher U, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:365–371.
   PubMed Web of Science ®Google Scholar
• Chen Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol. 2001;21:372–377.
   PubMed Web of Science ®Google Scholar
• el Azzouzi H, Leptidis S, Bourajjaj M, et al. MEK1 inhibits cardiac PPARalpha activity by direct interaction and prevents its nuclear localization. PLoS One. 2012;7:e36799.
   PubMed Web of Science ®Google Scholar